Apellis' Empaveli Poised To Give Soliris A Run In PNH
New Drug Reaches The Market With Broad Label And Competitive Pricing
Executive Summary
The first targeted C3 therapy was approved by the US FDA for treatment-naïve patients as well as those switching from Alexion's Soliris or Ultomiris.
You may also be interested in...
Apellis Follows Wave Life By Shelving ALS Candidate After Trial Miss
Apellis’s pegcetacoplan – approved for two other indications – will not go forward in amyotrophic lateral sclerosis after a Phase II failure, two days after Wave Life made a similar call in the neurodegenerative disease.
Iveric Bio Building Ophthalmology Commercial Team Ahead Of First Launch
CEO Glenn Sblendorio talked to Scrip about the company's plans to transition into a commercial-stage company after completing an NDA submission for its geographic atrophy drug in December.
NGM’s Second Phase II Miss Raises Questions For Option Deal With Merck
NGM said a Merck-partnered C3 inhibiting antibody has failed a Phase II study in geographic atrophy, after the biotech’s wholly owned NASH candidate missed in a Phase IIb study in 2021.